A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Trial Profile

A Phase 2, 12-Week, Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of a Range of SCH 420814 Doses in Subjects With Moderate to Severe Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesias

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Preladenant (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 01 Mar 2011 Results published in the Lancet Neurology.
    • 17 Dec 2008 Status changed from active, no longer recruiting to completed, according to clinicaltrials.gov.
    • 24 Nov 2008 Results are expected to be presented at the 13th International Congress of the Parkinson's Disease and Movement Disorders in June 2009 according to a Schering-Plough media release; results were also reported in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top